EASD 2023 Medfyle
Conference Coverage
In collaboration with
Welcome
Medfyle in collaboration with DESG is pleased to present the EASD 2023 Conference Coverage. This program offers a curated selection of the most impactful data presented at the meeting in a concise format, allowing you to catch up on groundbreaking insights in a fraction of the time. Access the key takeaways from EASD 2023, through bite-sized summaries, expert video interviews and topic deep dives, all at-a-glance and on-the-go.
Florian Toti, MD
Programme Chair
Interviews
Gain valuable insights from an international panel of experts.
Interpreting the results of SURMOUNT-4
8
Were there any surprises in the data from SURMOUNT-4?
79
Do the results of SURMOUNT-4 suggest that intermittent treatment may be possible?
169
What open questions remain after SURMOUNT-4?
SGLT2 inhibitors and GLP-1 receptor agonist: The kidney
8
How clinically relevant are the renal benefits of SGLT2 inhibitors and GLP-1 RAs?
82
Do all SGLT2 inhibitors and GLP-1 RAs have similar renal benefits?
134
For what patients are these agents indicated?
Dissecting the etiologies of autoimmune type 1 diabetes
8
How important is genetics in influencing autoimmune type 1 diabetes?
106
What role do environmental factors have in autoimmune type 1 diabetes?
196
What new therapies are in the pipeline for autoimmune type 1 diabetes?
Tirzepatide vs. insulin lispro in poorly controlled T2D
8
What were the key findings of the phase 3 trial comparing tirzepatide to insulin lispro as add-on to poorly controlled T2D?
158
What benefits might tirzepatide have over insulin lispro in this setting?
231
Do these results have the potential to change daily practice?
The link between NAFLD and type 2 diabetes
8
What is the physiological link between type 2 diabetes and NAFLD?
65
Does the common co-existence of NAFLD and type 2 diabetes have any implications for management?
145
Is NAFLD a cause or a consequence of type 2 diabetes?
More news from SGLT2s
8
What novel tehniques are being used to study fatty acid metabolism during treatment with SGLTi?
75
Is it safe for people to take SGLT2i when fasting during Ramadan?
136
What is known about the potential benefits of SGLT2i on microvasular complications?
185
Does everyone get equal access to SGLTis?
Artificial intelligence in diabetes care
8
Are any AI approaches already in routine use for diabetes?
40
What aspects of diabetes care can be improved through artifical intelligence?
103
What does the future hold in terms of use of AI in diabetes care?
SURMOUNT-4 Study efficacy and safety results
8
What were the key results from SURMOUNT-4?
132
Do the results of SURMOUNT-4 have the potential to change daily practice?
192
In what patients without diabetes might tirzepatide be indicated?
ADA/EASD consensus report on hyperglycaemic crises
8
Prof. Robert Gabbay, American Diabetes Association, Arlington, VA, USA
218
Prof. Gian Paolo Fadini, University of Padova, Padova, Italy
Triple G agonists
8
What exactly is a triple G agonist and what do these agents target?
114
What has been found in clinical trials with a triple G agonist?
239
Will triple G agonists render dual agonists obsolete?
Combining SGLT2 inhibitors and GLP-1 receptor agonists
8
Can combination therapy with SGLT2 inhibitors and GLP-1 RAs be expected to improve cardiovascular and/or renal outcomes?
110
What questions remain to be answered regarding the use of SGLT2 inhibitors and GLP-1 RAs in combination?
180
Can combination therapy with SGLT2 inhibitors and GLP-1 RAs be considered in all patients?
The importance of diabetes education
8
Why has education increasingly become a key component of effective diabetes treatment?
114
Can diabetes education be considered as a new empowering model?
197
What are the benefits of a structured diabetes education program?
Tirzepatide reduces muscle fat infiltration compared to insulin deglucec
8
What did the SURPASS-3 trial examine and what were the key findings?
48
What objectives did SURPASS-3 MRI have?
123
What implications do the results of SURPASS-3 MRI have?
Remission of type 2 diabetes in the real-world
8
What is meant by diabetes remission and what benefits does it have?
272
Is sustained remission of type 2 diabetes feasible in daily practice?
482
What are the biggest factors that can favor remission of type 2 diabetes?
SGLT2 inhibitors and GLP-1 related therapies: The liver
5
How clinically relevant are the hepatic benefits of SGLT2 inhibitors and GLP-1 related therapies?
95
Do all SGLT2 inhibitors and GLP-1 related therapies have similar hepatic benefits?
190
For what patients with renal impairment are SGLT2 inhibitors and GLP-1 related therapies indicated?
NEUROdiab Symposium: Diabetic neuropathy: new perspectives
8
Are some patients at greater risk of neuropathy than others?
139
What new approaches are being used to treat diabetic neuropathy?
274
What do clinicians need to know about screening and diagnosis of diabetic neuropathy?
Deep Dives
Watch on-demand videos, led by experts, to dive deeper into subjects of special interest.
Medfyle Summaries
From Oral Presentations
Missed the full presentation? Read at-a-glance summaries from a selection of oral presentations presented this year. Don’t forget to download the slide kits!
From Short Oral Presentations
Read at-a-glance summaries from a selection of short oral presentations.
Ask the Expert